An overview of sarcopenia: facts and numbers on prevalence and clinical impact
about
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old ratsRedox Characterization of Functioning Skeletal MuscleVitamin D signaling in myogenesis: potential for treatment of sarcopeniaOxidative system in aged skeletal muscleRelationship between human aging muscle and oxidative system pathwayVitamin E in sarcopenia: current evidences on its role in prevention and treatmentRationale for antioxidant supplementation in sarcopeniaMyopenia-a new universal term for muscle wastingPrevalence of sarcopenia in older Brazilians: A systematic review and meta-analysis.Age-associated differences in triceps surae muscle composition and strength - an MRI-based cross-sectional comparison of contractile, adipose and connective tissue.Identifying Sarcopenia in Metabolic Syndrome: Data from the Berlin Aging Study II.Are we closer to having drugs to treat muscle wasting disease?Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations.A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α.Respiratory chain deficiency in aged spinal motor neurons.The impact of low muscle mass definition on the prevalence of sarcopenia in older Australians.The intriguing regulators of muscle mass in sarcopenia and muscular dystrophy.Longitudinal impact of aging on muscle quality in middle-aged menAge-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseasesEfforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention.Muscle wasting: an overview of recent developments in basic research.Sarcopenia with limited mobility: an international consensus.Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference.Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.Exercise attenuates the major hallmarks of aging.Moving on up: the Journal of Cachexia, Sarcopenia and Muscle.Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014.Cachexia in heart disease: highlights from the ESC 2010Evaluation of early biomarkers of muscle anabolic response to testosteroneOxidative stress induces caveolin 1 degradation and impairs caveolae functions in skeletal muscle cells.The role of myostatin in muscle wasting: an overviewThe epidemiology of sarcopenia in community living older adults: what role does lifestyle play?Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexiaPrevalence and definition of sarcopenia in community dwelling older people. Data from the Berlin aging study II (BASE-II).Meal-based enhancement of protein quality and quantity during weight loss in obese older adults with mobility limitations: rationale and design for the MEASUR-UP trial.Not being able to see the muscle for the fat.Plasma heat shock protein 72 as a biomarker of sarcopenia in elderly people.Sarcopenia and Hearing Loss in Older Koreans: Findings from the Korea National Health and Nutrition Examination Survey (KNHANES) 2010Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.Evolving concepts on the age-related changes in "muscle quality".
P2860
Q24564273-A82F1851-87B8-4825-9C16-EC86A1F2BAC4Q26774782-60341AF8-CA60-412A-8E8E-BF6487CFEF14Q26849642-8326E305-60F5-40A9-9D17-08CE552D69DAQ28383588-110F395A-1965-494C-9B8F-B65370893B98Q28385037-FFE41516-77CF-4071-AA71-06621EE6AA18Q28390862-0B042217-744F-4524-A93D-8A2947006775Q28395964-35A8E4E1-2093-4C4C-B7C7-5BE76BBEED72Q28741675-05D7C585-A93F-40F9-A6AC-44759DC94691Q30251945-2828303D-2394-4289-BBB9-DD382472B6D3Q30831831-A59D59EC-E65C-4343-858C-3015341988A3Q30986817-FCA814A9-978A-4096-A2F7-32978CDD145EQ33741103-AC3A950D-1717-4D08-B285-11611A5AEE1DQ33828935-48E7B0EB-07C2-4855-88FA-7A3274FD6B95Q33901304-3E5CAB15-E7C7-4AD3-AD03-E28C7DD8F052Q33906482-A80D1AAC-FCF3-4CB6-B188-291EA11C1728Q33930382-42B079D6-A9E7-4E6A-A840-338812C81525Q34106342-33EC3144-6F09-40FE-A728-3964B29ECA97Q34115979-B403DF9D-DA58-4C3B-9117-66AF7F4B145DQ34145591-433A0B97-A2FC-4171-8C9D-75FB314800AEQ34156932-4CED3526-FD2A-435A-B13E-A273A4DD1D46Q34156942-70D0EBA8-7253-4167-87E4-1861E269A66DQ34189767-6ECEC5F3-6E37-40F5-B9E3-2EF008544060Q34264508-8A7734DE-70E4-4CE6-B3D6-9524EE128BC3Q34334313-9424C0BA-C180-42C0-8A77-2042B21E9045Q34449998-72639A04-FC5E-4945-A6BA-549603D8854FQ34495485-CABBB2E3-4A38-43CA-939E-9D912B94E48EQ34591010-B778F51A-5C02-45ED-BB0C-4D0A5113F203Q34716880-2E53B5CE-EFB4-4E02-9ECF-A27BEEA1C596Q34716895-2AD18050-659C-456C-B9A2-DA115C8B4AE0Q35208361-176020C1-4473-41DF-828D-2B9B06C06D9EQ35223987-3E37D070-36CF-4EBF-813B-6577430A2631Q35223989-96F23B63-13DC-4579-9EC7-488394882F2DQ35569439-E9522FD3-665C-4833-9CCA-0F822577FDBCQ35602843-2DF96CA8-7576-41B0-A0E0-7CBBD8359F1CQ35626325-DFA83B73-8485-4C18-AAEE-90390CB8BC3FQ35828094-3F146767-83D9-4479-881A-CF94BD5E6548Q35854605-B7C5B2F3-17DE-4B76-993D-1BCCE8DA926EQ35957935-ECE3AC4F-A614-4A40-B87B-579E067F2D6DQ36028202-F3CB2E5F-AAF9-4394-B999-9A62C0BE0B18Q36028216-A83DB330-8125-49A3-8161-08CDBB09A2B2
P2860
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@ast
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@en
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@nl
type
label
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@ast
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@en
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@nl
prefLabel
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@ast
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@en
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@nl
P2860
P3181
P1476
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
@en
P2093
John E Morley
P2860
P304
P3181
P356
10.1007/S13539-010-0014-2
P577
2010-12-01T00:00:00Z